Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Selective inhibitor studies in macrophages implicate class II HDAC enzymes in TLR-mediated inflammatory pathways and class I HDACs as negative regulators. Broad-spectrum inhibitors of HDACs are therapeutic in many inflammatory disease models but exacerbated disease in a mouse model of atherosclerosis. HDAC inhibitors have anti- and proinflammatory effects on macrophages in vitro. We report here that several broad-spectrum HDAC inhibitors, including TSA and SAHA, suppressed the LPS-induced mRNA expression of the proinflammatory mediators Edn-1, Ccl-7/MCP-3, and Il-12p40 but amplified the expression of the proatherogenic factors Cox-2 and Pai-1/serpine1 in primary mouse BMM. Similar effects were also apparent in LPS-stimulated TEPM and HMDM. The pro- and anti-inflammatory effects of TSA were separable over a concentration range, implying that individual HDACs have differential effects on macrophage inflammatory responses. The HDAC1-selective inhibitor, MS-275, retained proinflammatory effects (amplification of LPS-induced expression of Cox-2 and Pai-1 in BMM) but suppressed only some inflammatory responses. In contrast, 17a (a reportedly HDAC6-selective inhibitor) retained anti-inflammatory but not proinflammatory properties. Despite this, HDAC6−/− macrophages showed normal LPS-induced expression of HDAC-dependent inflammatory genes, arguing that the anti-inflammatory effects of 17a are not a result of inhibition of HDAC6 alone. Thus, 17a provides a tool to identify individual HDACs with proinflammatory properties.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As drug inhibition of cellular deacetylases strongly attenuates pathogen-and immunogen-induced immune responses (139–141), it is tempting to speculate that acetylation plays a key role in modulating immune signaling pathways.”
From The Impact of Mass Spectrometry–Based Proteomics on Fundamental Discoveries in Virology (2014) · cites this paper as [139]
Citations
Cites
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Butyrate inhibits inflammatory responses through NFκB inhibition: implications for Crohn's disease
Segain, J.-P., de la Blétière, D. R., Bourreille, A., Leray, V, Gervois, N., Rosales, C., Ferrier, L., Bonnet, C., Blottière, H. M., & Galmiche, J.-P. (2000) · Gut · doi:10.1136/gut.47.3.397 · Cited by 1,321
Marks, P. A., & Breslow, R. (2007) · Nature Biotechnology · doi:10.1038/nbt1272 · Cited by 1,196
Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0430973100 · Cited by 1,066
Histone Deacetylase Inhibitors in Cancer Therapy
Lane, A. A., & Chabner, B. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1291 · Cited by 874
Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression
Lagger, G., O'Carroll, D., Rembold, M., Khier, H., Tischler, J., Weitzer, G., Schuettengruber, B., Hauser, C., Brunmeir, R., Jenuwein, T., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/21.11.2672 · Cited by 760 · cited 2×
“To assess the selectivity of MS-275, compound 17a, and compound 7 in macrophages, we first examined the hyperacetylation of HDAC substrates, HDAC1 and HDAC6 deacetylate histone H3, [35] and -tubulin [39], respectively.”
BackgroundIto, K., Yamamura, S., Essilfie-Quaye, S., Cosio, B., Ito, M., Barnes, P. J., & Adcock, I. M. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20050466 · Cited by 638
Histone acetylation and deacetylation: importance in inflammatory lung diseases
Barnes, P. J., Adcock, I. M., & Ito, K. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00117504 · Cited by 564
Mice Lacking Histone Deacetylase 6 Have Hyperacetylated Tubulin but Are Viable and Develop Normally
Zhang, Y., Kwon, S., Yamaguchi, T., Cubizolles, F., Rousseaux, S., Kneissel, M., Cao, C., Li, N., Cheng, H.-L., Chua, K., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01154-06 · Cited by 559 · cited 1×
“To assess the selectivity of MS-275, compound 17a, and compound 7 in macrophages, we first examined the hyperacetylation of HDAC substrates, HDAC1 and HDAC6 deacetylate histone H3, [35] and -tubulin [39], respectively.”
BackgroundSelf-citation
Cited by
Regulation of inflammation by short chain fatty acids
Vinolo, M. A. R., Rodrigues, H. G., Nachbar, R. T., & Curi, R. (2011) · Nutrients · doi:10.3390/nu3100858 · Cited by 1,724
Pro- and anti-inflammatory effects of short chain fatty acids on immune and endothelial cells
Li, M., van Esch, B. C. A. M., Wagenaar, G. T. M., Garssen, J., Folkerts, G., & Henricks, P. A. J. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.05.003 · Cited by 614
Histone deacetylases as regulators of inflammation and immunity
Shakespear, M. R., Halili, M. A., Irvine, K. M., Fairlie, D. P., & Sweet, M. J. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.04.001 · Cited by 546
Self-citationHDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases
Yoon, S., & Eom, G. H. (2016) · Chonnam Medical Journal · doi:10.4068/cmj.2016.52.1.1 · Cited by 464
Regulation of short-chain fatty acids in the immune system
Liu, X.-F., Shao, J.-H., Liao, Y.-T., Wang, L.-N., Jia, Y., Dong, P.-J., Liu, Z.-Z., He, D.-D., Li, C., & Zhang, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1186892 · Cited by 403
Xie, M., Kong, Y., Tan, W., May, H., Battiprolu, P. K., Pedrozo, Z., Wang, Z. V., Morales, C., Luo, X., Cho, G., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.002416 · Cited by 326
HDAC inhibitor‐based therapies: Can we interpret the code?
New, M., Olzscha, H., & La Thangue, N. B. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.003 · Cited by 310
SCFAs Induce Mouse Neutrophil Chemotaxis through the GPR43 Receptor
Vinolo, M. A. R., Ferguson, G. J., Kulkarni, S., Damoulakis, G., Anderson, K., Bohlooly-Y, M., Stephens, L., Hawkins, P. T., & Curi, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021205 · Cited by 292
Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus
Christensen, D. P., Dahllöf, M., Lundh, M., Rasmussen, D. N., Nielsen, M. D., Billestrup, N., Grunnet, L. G., & Mandrup-Poulsen, T. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00021 · Cited by 261
Araújo, J. R., Tomas, J., Brenner, C., & Sansonetti, P. J. (2017) · Biochimie · doi:10.1016/j.biochi.2017.05.019 · Cited by 261
Epigenetic mechanisms in diabetic vascular complications
Reddy, M. A., & Natarajan, R. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvr024 · Cited by 199
“tors surprisingly suppressed a subset of inflammatory genes but increased pro-atherogenic genes, suggesting that further studies are needed to clarify their role in atherosclerosis and inflammation.(94,95)”
BackgroundLi, X., Zhang, Q., Ding, Y., Liu, Y., Zhao, D., Zhao, K., Shen, Q., Liu, X., Zhu, X., Li, N., et al. (2016) · Nature Immunology · doi:10.1038/ni.3464 · Cited by 190
Host modulation therapy with anti‐inflammatory agents
Preshaw, P. M. (2018) · Periodontology 2000 · doi:10.1111/prd.12148 · Cited by 188
Cao, Q., Rong, S., Repa, J. J., Clair, R. S., Parks, J. S., & Mishra, N. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.303393 · Cited by 185
Yuan, X., Wang, L., Bhat, O. M., Lohner, H., & Li, P. (2018) · Redox Biology · doi:10.1016/j.redox.2018.02.007 · Cited by 168
HDAC inhibitors and immunotherapy; a double edged sword?
Kroesen, M., Gielen, P. R., Brok, I. C., Armandari, I., Hoogerbrugge, P. M., & Adema, G. J. (2014) · Oncotarget · doi:10.18632/oncotarget.2289 · Cited by 166
Li, X., Su, X., Liu, R., Pan, Y., Fang, J., Cao, L., Feng, C., Shang, Q., Chen, Y., Shao, C., et al. (2021) · Oncogene · doi:10.1038/s41388-020-01636-x · Cited by 160
Histone Deacetylase Inhibitors for Treating a Spectrum of Diseases Not Related to Cancer
Dinarello, C. A., Fossati, G., & Mascagni, P. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00116 · Cited by 159
Li, W., Ali, T., Zheng, C., Liu, Z., He, K., Shah, F. A., Ren, Q., Rahman, S. U., Li, N., Yu, Z.-J., et al. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02091-5 · Cited by 145
Histone deacetylase 3 (HDAC 3) as emerging drug target in NF-κB-mediated inflammation
Leus, N. G., Zwinderman, M. R., & Dekker, F. J. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2016.06.019 · Cited by 150
Suberoylanilide Hydroxamic Acid (Vorinostat) Up-regulates Progranulin Transcription
Cenik, B., Sephton, C. F., Dewey, C. M., Xian, X., Wei, S., Yu, K., Niu, W., Coppola, G., Coughlin, S. E., Lee, S. E., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.193433 · Cited by 147
Daskalaki, M. G., Tsatsanis, C., & Kampranis, S. C. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26497 · Cited by 139
Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
Banik, D., Moufarrij, S., & Villagra, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092241 · Cited by 133
Epigenetic regulation of macrophage polarization in wound healing
Chen, C., Liu, T., Tang, Y., Luo, G., Liang, G., & He, W. (2023) · Burns & Trauma · doi:10.1093/burnst/tkac057 · Cited by 142
de Groot, A. E., & Pienta, K. J. (2018) · Oncotarget · doi:10.18632/oncotarget.24556 · Cited by 135
Sodium butyrate alleviates adipocyte inflammation by inhibiting NLRP3 pathway
Wang, X., He, G., Peng, Y., Zhong, W., Wang, Y., & Zhang, B. (2015) · Scientific Reports · doi:10.1038/srep12676 · Cited by 130
Das Gupta, K., Shakespear, M. R., Iyer, A., Fairlie, D. P., & Sweet, M. J. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2015.46 · Cited by 115
Self-citationIsaacs, J. T., Antony, L., Dalrymple, S. L., Brennen, W. N., Gerber, S., Hammers, H., Wissing, M., Kachhap, S., Luo, J., Xing, L., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2730 · Cited by 116
Inflammation‐induced sensitization of the brain in term infants
Fleiss, B., Tann, C. J., Degos, V., Sigaut, S., Van Steenwinckel, J., Schang, A., Kichev, A., Robertson, N. J., Mallard, C., Hagberg, H., et al. (2015) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.12723 · Cited by 103
Transcriptional profiling identifies novel regulators of macrophage polarization
Gerrick, K. Y., Gerrick, E. R., Gupta, A. K., Wheelan, S. J., Yegnasubramanian, S., & Jaffee, E. M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0208602 · Cited by 115
Kannan, V., Brouwer, N., Hanisch, U.-K., Regen, T., Eggen, B. J. L., & Boddeke, H. W. G. M. (2013) · Journal of Neuroscience Research · doi:10.1002/jnr.23221 · Cited by 107
Kapellos, T. S., & Iqbal, A. J. (2016) · Mediators of Inflammation · doi:10.1155/2016/6591703 · Cited by 106
Cheng, F., Lienlaf, M., Wang, H.-W., Perez-Villarroel, P., Lee, C., Woan, K., Rock-Klotz, J., Sahakian, E., Woods, D., Pinilla-Ibarz, J., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302778 · Cited by 106
Gupta, K. D., Shakespear, M. R., Curson, J. E. B., Murthy, A. M. V., Iyer, A., Hodson, M. P., Ramnath, D., Tillu, V. A., von Pein, J. B., Reid, R. C., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.02.007 · Cited by 106
Self-citationShakespear, M. R., Hohenhaus, D. M., Kelly, G., Kamal, N. A., Gupta, P. K., Labzin, L. I., Schroder, K., Garceau, V., Barbero, S., Iyer, A., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.496281 · Cited by 105
Self-citationPosttranslational modifications of histone deacetylases: Implications for cardiovascular diseases
Eom, G. H., & Kook, H. Y. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.02.012 · Cited by 105
Gu, L.-Z., Sun, H., & Chen, J. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.11.094 · Cited by 103
Innate and Adaptive Immunity in Cystic Fibrosis
Bruscia, E. M., & Bonfield, T. L. (2015) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2015.11.010 · Cited by 100
Kim, Y., Park, S.-M., Ha, H. C., Lee, A. R., Won, H., Cha, H., Cho, S., & Cho, J. M. (2020) · Journal of Cancer · doi:10.7150/jca.44622 · Cited by 97
Loos, M., Geens, M. M., Schauvliege, S., Gasthuys, F., van der Meulen, J., Dubreuil, J. D., Goddeeris, B. M., Niewold, T., & Cox, E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041041 · Cited by 94
Targeting FoxO transcription factors with HDAC inhibitors for the treatment of osteoarthritis
Ohzono, H., Hu, Y., Nagira, K., Kanaya, H., Okubo, N., Olmer, M., Gotoh, M., Kurakazu, I., Akasaki, Y., Kawata, M., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2021-221269 · Cited by 92
Kobayashi, T., Matsuoka, K., Sheikh, S. Z., Russo, S. M., Mishima, Y., Collins, C., deZoeten, E. F., Karp, C. L., Ting, J. P. Y., Sartor, R. B., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200042 · Cited by 82
Hsing, C., Hung, S., Chen, Y.-C., Wei, T.-S., Sun, D., Wang, J.-J., & Yeh, C. (2015) · Mediators of Inflammation · doi:10.1155/2015/163140 · Cited by 86
Bandyopadhaya, A., Tsurumi, A., Maura, D., Jeffrey, K. L., & Rahme, L. G. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.174 · Cited by 86
Manea, S., Vlad, M.-L., Fenyo, I. M., Lazar, A.-G., Raicu, M., Mureşian, H., Simionescu, M., & Manea, A. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101338 · Cited by 85
Rossi, L. E., Avila, D. E., Spallanzani, R. G., Ziblat, A., Fuertes, M. B., Lapyckyj, L., Croci, D. O., Rabinovich, G. A., Domaica, C. I., & Zwirner, N. W. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0711339 · Cited by 84
Discovery of functionally selective C5aR2 ligands: novel modulators of C5a signalling
Croker, D. E., Monk, P. N., Halai, R., Kaeslin, G., Schofield, Z., Wu, M. C. L., Clark, R. J., Blaskovich, M. A. T., Morikis, D., Floudas, C. A., et al. (2016) · Immunology and Cell Biology · doi:10.1038/icb.2016.43 · Cited by 84
Liu, J.-R., Yu, C.-W., Hung, P.-Y., Hsin, L.-W., & Chern, J.-W. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.03.023 · Cited by 82
HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation
Sweet, M. J., Shakespear, M. R., Kamal, N. A., & Fairlie, D. P. (2012) · Immunology & Cell Biology · doi:10.1038/icb.2011.88 · Cited by 77
Self-citationHDAC inhibitor therapy in autoimmunity and transplantation
Hancock, W. W., Akimova, T., Beier, U. H., Liu, Y., & Wang, L. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200593 · Cited by 80
Leus, N. G. J., van den Bosch, T., van der Wouden, P. E., Krist, K., Ourailidou, M. E., Eleftheriadis, N., Kistemaker, L. E. M., Bos, S., Gjaltema, R. A. F., Mekonnen, S. A., et al. (2017) · Scientific Reports · doi:10.1038/srep45047 · Cited by 76
Epigenetic pathways in macrophages emerge as novel targets in atherosclerosis
Neele, A. E., den Bossche, J. V., Hoeksema, M. A., & de Winther, M. P. J. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.101 · Cited by 79
Cantley, M. D., & Haynes, D. R. (2013) · Inflammopharmacology · doi:10.1007/s10787-012-0166-0 · Cited by 77
Carpio, L. R., Bradley, E. W., McGee-Lawrence, M. E., Weivoda, M. M., Poston, D. D., Dudakovic, A., Xu, M., Tchkonia, T., Kirkland, J. L., van Wijnen, A. J., et al. (2016) · Science Signaling · doi:10.1126/scisignal.aaf3273 · Cited by 74
Epigenetic mechanisms of macrophage activation in type 2 diabetes
Ahmed, M., de Winther, M. P. J., & den Bossche, J. V. (2016) · Immunobiology · doi:10.1016/j.imbio.2016.08.011 · Cited by 75
Chistiakov, D. A., Orekhov, A. N., & Bobryshev, Y. V. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.204 · Cited by 74
Inhibiting epigenetic enzymes to improve atherogenic macrophage functions
den Bossche, J. V., Neele, A. E., Hoeksema, M. A., de Heij, F., Boshuizen, M. C. S., van der Velden, S., de Boer, V. C. J., Reedquist, K. A., & de Winther, M. P. J. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.11.029 · Cited by 73
Toussirot, É., Abbas, W., Khan, K. A., Tissot, M., Jeudy, A., Baud, L., Bertolini, E., Wendling, D., & Herbein, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070939 · Cited by 68
The Impact of Mass Spectrometry–Based Proteomics on Fundamental Discoveries in Virology
Greco, T. M., Diner, B. A., & Cristea, I. M. (2014) · Annual Review of Virology · doi:10.1146/annurev-virology-031413-085527 · Cited by 67
Histone Deacetylase Inhibitors as Immunomodulators in Cancer Therapeutics
Shen, L., Orillion, A., & Pili, R. (2016) · Epigenomics · doi:10.2217/epi.15.118 · Cited by 65
Toki, S., Goleniewska, K., Reiss, S., Zhou, W., Newcomb, D. C., Bloodworth, M. H., Stier, M. T., Boyd, K. L., Polosukhin, V. V., Subramaniam, S., et al. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207728 · Cited by 64
Li, H., Chen, X., & Li, M. (2013) · Europe PMC (PubMed Central) · Cited by 65
Histone deacetylases and atherosclerosis
Zheng, X., Zhou, T., Wang, X., Tong, X.-H., & Ding, J. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.12.048 · Cited by 63
Host HDAC4 regulates the antiviral response by inhibiting the phosphorylation of IRF3
Yang, Q., Tang, J., Pei, R., Gao, X., Guo, J., Xu, C., Wang, Y., Wang, Q., Wu, C., Zhou, Y., et al. (2018) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy035 · Cited by 63
Gao, J., Wang, D., Liu, D., Liu, M., Ge, Y., Jiang, M., Liu, Y., & Zheng, D. (2015) · Molecular Biology of the Cell · doi:10.1091/mbc.e15-04-0209 · Cited by 60
Valproic Acid Attenuates Lipopolysaccharide-Induced Acute Lung Injury in Mice
Ji, M., Li, G.-M., Jia, M., Zhu, S., Gao, D., Fan, Y., Wu, J., & Yang, J. (2013) · Inflammation · doi:10.1007/s10753-013-9686-z · Cited by 58
Histone deacetylase–mediated silencing of AMWAP expression contributes to cisplatin nephrotoxicity
Ranganathan, P., Hamad, R., Mohamed, R., Jayakumar, C., Muthusamy, T., & Ramesh, G. (2016) · Kidney International · doi:10.1038/ki.2015.326 · Cited by 55
Neudorf, H., Durrer, C. G., Myette‐Côté, É., Makins, C., O’Malley, T., & Little, J. P. (2019) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201801171 · Cited by 58
Macrophage polarization in response to oral commensals and pathogens
Huang, C. B., Alimova, Y. V., & Ebersole, J. L. (2016) · Pathogens and Disease · doi:10.1093/femspd/ftw011 · Cited by 55
Epigenetic mechanisms of hyperglycemic memory
Cencioni, C., Spallotta, F., Greco, S., Martelli, F., Zeiher, A. M., & Gaetano, C. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.04.014 · Cited by 54
Differential Anti-inflammatory Activity of HDAC Inhibitors in Human Macrophages and Rat Arthritis
Lohman, R., Iyer, A., Fairlie, T., Cotterell, A. J., Gupta, P. K., Reid, R. C., Vesey, D. A., Sweet, M. J., & Fairlie, D. P. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.229328 · Cited by 55
Self-citationInterplay Between Inflammation and Epigenetic Changes in Cancer
Maiuri, A. R., & O’Hagan, H. M. (2016) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2016.09.002 · Cited by 55
Cosenza, M., Civallero, M., Marcheselli, L., Sacchi, S., & Pozzi, S. (2017) · APOPTOSIS · doi:10.1007/s10495-017-1364-4 · Cited by 54
Doherty, R., O’Farrelly, C., & Meade, K. G. (2013) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2013.05.004 · Cited by 54
Inflammation and histone modification in chronic pain
Jiang, W., Li-xi, Z., Tan, X.-Y., Yu, P., & Dong, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1087648 · Cited by 55
Qu, X., Pröll, M. J., Neuhoff, C., Zhang, R., Çınar, M. U., Hossain, M. M., Tesfaye, D., Große‐Brinkhaus, C., Salilew‐Wondim, D., Tholen, E., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121574 · Cited by 53
Wang, P., Mao, Z., Pan, Q., Lu, R., Huang, X., Shang, X., Zhang, R., & You, H. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3410 · Cited by 53
Zhang, Y., Gao, Y., Jiang, Y., Ding, Y., Chen, H., Yan, X. Y., Zhan, Z., & Liu, X. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01136-x · Cited by 52
Kim, J. I., Jung, K.-J., Jang, H., & Park, K. M. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00015.2013 · Cited by 50
Impact of HDAC inhibitors on macrophage polarization to enhance innate immunity against infections
Bhat, M. F., Srdanović, S., Sundberg, L.-R., Einarsdottir, H., Marjomäki, V., & Dekker, F. J. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104193 · Cited by 49
Acetylation of TIR domains in the TLR4-Mal-MyD88 complex regulates immune responses in sepsis
Li, X., Li, X., Huang, P., Zhang, F., Du, J. K., Kong, Y., Shao, Z., Wu, X., Fan, W., Tao, H., et al. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00237-8 · Cited by 49
Histone deacetylase 3 promotes innate antiviral immunity through deacetylation of TBK1
Tang, J., Yang, Q., Xu, C., Zhao, H., Liu, Y., Liu, C.-Y., Zhou, Y., Gai, D.-W., Pei, R., Wang, Y., et al. (2020) · Protein & Cell · doi:10.1007/s13238-020-00751-5 · Cited by 48
del Campo, C. M. Z.-M., Rosas, M., & Guarner‐Lans, V. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041224 · Cited by 46
Stammler, D., Eigenbrod, T., Menz, S., Frick, J.-S., Sweet, M. J., Shakespear, M. R., Jantsch, J., Siegert, I., Wölfle, S. J., Langer, J. D., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1501195 · Cited by 47
Self-citationAdvances in immunotherapy for the treatment of spinal cord injury
Mamun, A. A., Monalisa, I., Kubra, K. T., Akter, A., Akter, J., Sarker, T., Munir, F., Wu, Y., Jia, C., Taniya, M. A., et al. (2020) · Immunobiology · doi:10.1016/j.imbio.2020.152033 · Cited by 46
Anti-Inflammatory Effects of Spirulina platensis Extract via the Modulation of Histone Deacetylases
Pham, T., Park, Y.-K., & Lee, J.-Y. (2016) · Nutrients · doi:10.3390/nu8060381 · Cited by 44
Histone Deacetylases in Herpesvirus Replication and Virus-Stimulated Host Defense
Guise, A., Budayeva, H., Diner, B., & Cristea, I. (2013) · Viruses · doi:10.3390/v5071607 · Cited by 43
“Indeed, increasing evidence suggests that HDACs are regulators of inflammatory response, immune signaling and myeloid differentiation [71] [72] [73] [74] .”
BackgroundKrajewski, D., Kaczenski, E., Rovatti, J., Polukort, S., Thompson, C., Dollard, C. A., Ser‐Dolansky, J., Schneider, S. S., Kinney, S. R. M., & Mathias, C. B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02414 · Cited by 43
Kallsen, K., Andresen, E., & Heine, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050000 · Cited by 41
Cytokines and pregnancy: Potential regulation by histone deacetylases
Munro, S. K., Balakrishnan, B., Lissaman, A. C., Gujral, P., & Ponnampalam, A. P. (2021) · Molecular Reproduction and Development · doi:10.1002/mrd.23430 · Cited by 39
Kulthinee, S., Yano, N., Zhuang, S., Wang, L., & Zhao, T. C. (2022) · Pathophysiology · doi:10.3390/pathophysiology29030038 · Cited by 39
Nguyen, A. H., Elliott, I. A., Wu, N., Matsumura, C., Vogelauer, M., Attar, N., Dann, A. M., Ghukasyan, R., Toste, P. A., Patel, S. G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13572 · Cited by 38
Role of Epigenetic Mechanisms in the Vascular Complications of Diabetes
Reddy, M. A., & Natarajan, R. D. (2012) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-4525-4_19 · Cited by 38
Identifying cisplatin-induced kidney damage in paediatric oncology patients
Barton, C. D., Pizer, B. L., Jones, C. A., Oni, L., Pirmohamed, M., & Hawcutt, D. B. (2017) · Pediatric Nephrology · doi:10.1007/s00467-017-3765-6 · Cited by 36
Weiss, U., Möller, M., Husseini, S. A., Manderscheid, C., Häusler, J., Geißlinger, G., & Niederberger, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238943 · Cited by 35
New Insight in HDACs: Potential Therapeutic Targets for the Treatment of Atherosclerosis
Luan, Y., Liu, H., Luan, Y., Yang, Y., Yang, J., & Ren, K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.863677 · Cited by 34
Zhou, X., Hua, X., Ding, X., Bian, Y., & Wang, X. (2011) · Journal of Clinical Immunology · doi:10.1007/s10875-011-9508-8 · Cited by 34
Chong, W., Li, Y., Liu, B., Zhao, T., Fukudome, E. Y., Liu, Z., Smith, W. M., Velmahos, G. C., DeMoya, M. A., & Alam, H. B. (2012) · Journal of Surgical Research · doi:10.1016/j.jss.2012.07.023 · Cited by 33
Park, J., Kim, Y., Lee, C.-H., & Kim, Y. T. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113549 · Cited by 33
Inhibitors selective for HDAC6 in enzymes and cells
Gupta, P. K., Reid, R. C., Liu, L., Lucke, A. J., Broomfield, S., Andrews, M. R., Sweet, M. J., & Fairlie, D. P. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.09.100 · Cited by 33
Self-citation
Metadata
- Authors
- Halili, M. A., Andrews, M. R., Labzin, L. I., Schroder, K., Matthias, G., Cao, C., Lovelace, E., Reid, R. C., Le, G. T., Hume, D. A., Irvine, K. M., Matthias, P., Fairlie, D. P., & Sweet, M. J.
- Affiliations
- The University of Queensland (AU)
- University of Lausanne (CH)
- Friedrich Miescher Institute (CH)
- Roslin Institute (GB)
- Corresponding author
- Sweet, Matthew J
- ORCID
- Venue
- Journal of Leukocyte Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-03-03
- Volume
- 87
- Issue
- 6
- Pages
- 1103-1114
- ISSN
- 0741-5400 (ISSN-L)
- 1938-3673
- OpenAlex
- W2114231153
- Cited by
- 186
- References
- 51
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 6 · 2023: 9 · 2022: 8 · 2021: 11 · 2020: 16 · 2019: 5 · 2018: 13 · 2017: 8 · 2016: 26 · 2015: 15 · 2014: 13 · 2013: 17 · 2012: 16
- FWCI
- 6.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Leukocyte Biology (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- ARC Special Research Centre for Functional and Applied Genomics
- Cancer Council Queensland (511205)
- Australian National Health and Medical Research Council (569735)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Keywords
- histone deacetylase inhibitors, macrophage inflammation, TLR4, lipopolysaccharide, atherosclerosis, trichostatin A, vorinostat, entinostat, HDAC6, HDAC1, cyclooxygenase-2, plasminogen activator inhibitor-1, IL-12, macrophages
- MeSH terms
- Histone Deacetylase 6, Vorinostat, Animals, Enzyme-Linked Immunosorbent Assay, Histone Deacetylases, Hydroxamic Acids, Inflammation, Lipopolysaccharides, Luciferases, Macrophages, Male, Mice, Inbred C57BL, RNA, Messenger, Blotting, Western, Plasminogen Activator Inhibitor 1, Mice, Knockout, Inflammation Mediators, Reverse Transcriptase Polymerase Chain Reaction, Chromatin Immunoprecipitation, Toll-Like Receptor 4, Mice, Cyclooxygenase 2, Interleukin-12 Subunit p40, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.